Meridian Investment Counsel’s Ligand Pharmaceuticals LGND Stock Holding History

Meridian Investment Counsel’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,200	Closed	-$356K	–	181
2018 Q4	$356K	Sell	4,200 -761	-15%	-$81.1K	0.23%	106
2018 Q3	$850K	Sell	4,961 -80	-2%	-$12.1K	0.46%	66
2018 Q2	$652K	Hold	5,041	–	–	0.37%	77
2018 Q1	$519K	Hold	5,041	–	–	0.29%	92
2017 Q4	$431K	Sell	5,041 -41	-0.8%	-$3.55K	0.23%	106
2017 Q3	$432K	Hold	5,082	–	–	0.25%	104
2017 Q2	$385K	Hold	5,082	–	–	0.23%	110
2017 Q1	$336K	Hold	5,082	–	–	0.21%	130
2016 Q4	$322K	Buy	5,082 +81	+2%	+$5.11K	0.22%	124
2016 Q3	$318K	Buy	5,001 +320	+7%	+$23.5K	0.21%	123
2016 Q2	$348K	Buy	4,681 +48	+1%	+$3.56K	0.24%	114
2016 Q1	$309K	Buy	+4,633	New	+$282K	0.22%	121

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Meridian Investment Counsel's LGND Position: Q1 2019 in Review

Meridian Investment Counsel sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 4,200 shares — an estimated $356K sold.

Meridian Investment Counsel first reported a position in LGND in Q1 2016 and held it in 12 quarters. The position peaked at $850K in Q3 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

Meridian Investment Counsel reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Meridian Investment Counsel sold 4,200 Ligand Pharmaceuticals shares in Q1 2019, an estimated $356K.
Meridian Investment Counsel first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 12 quarters.
Meridian Investment Counsel's Ligand Pharmaceuticals position peaked at $850K in Q3 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Meridian Investment Counsel's 13F filing for Q1 2019, filed 6 May 2019.